Uni-Bio Science Group Limited (HKG:0690)
Hong Kong · Delayed Price · Currency is HKD 0.1150
+0.0010 (0.88%)
At close: Feb 13, 2026
Uni-Bio Science Group Revenue
Uni-Bio Science Group had revenue of 310.23M HKD in the half year ending June 30, 2025, with 24.12% growth. This brings the company's revenue in the last twelve months to 589.59M, up 15.97% year-over-year. In the year 2024, Uni-Bio Science Group had annual revenue of 552.98M with 14.08% growth.
Revenue (ttm)
589.59M
Revenue Growth
+15.97%
P/S Ratio
1.16
Revenue / Employee
1.17M
Employees
504
Market Cap
686.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 552.98M | 68.26M | 14.08% |
| Dec 31, 2023 | 484.72M | 44.40M | 10.08% |
| Dec 31, 2022 | 440.32M | 86.91M | 24.59% |
| Dec 31, 2021 | 353.41M | 144.63M | 69.27% |
| Dec 31, 2020 | 208.78M | -673.00K | -0.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 491.34M |
| JW (Cayman) Therapeutics Co. | 194.77M |
| Wuhan YZY Biopharma | 163.65M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Brii Biosciences | 31.53M |
| Kintor Pharmaceutical | 12.04M |
| Transcenta Holding | 10.31M |
Uni-Bio Science Group News
- 1 year ago - Uni-Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches : Pioneering Entry into the High-Growth Medical Aesthetics Market - Zawya